Physician profile
Laura Lamonica
NPI 1023655974
$2,932.35
in general payments reported to CMS, 2019-2025
21 companies · $814 in 2025
The $814 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $445 · 2023: $678 · 2024: $474 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,966.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.52 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $338.05 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $234.09 | 2021-2025 | Spravato |
| Tris Pharma INC | $231.35 | 2023-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $185.03 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.04 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $176.52 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $171.10 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $134.60 | 2021-2025 | Trintellix |
| Corium, LLC | $130.86 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $85.05 | 2025 | Jornay Pm |
| Lundbeck LLC | $76.45 | 2021-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $74.17 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $55.95 | 2022-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $51.91 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $45.43 | 2021-2023 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $34.01 | 2021 | |
| Axsome Therapeutics, INC. | $28.51 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $19.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.30 | 2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $15.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Lamonica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.